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Abstract
To determine cervical cancer risk associated with contemporary hormonal contracep-
tives, we conducted a cohort study of women aged 15 to 49 living in Denmark from
1995 to 2014, using routinely collected information about redeemed prescriptions,
incident cancer and potential confounders. Poisson regression calculated adjusted cer-
vical cancer risks among different contraceptive user groups by duration of use, time
since last use, hormonal content and cancer histology. During >20 million person-
years, 3643 incident cervical cancers occurred. Ever users of any hormonal contracep-
tives compared to never users had a relative risk (RR) of 1.19 (95% confidence interval
[CI] 1.10-1.29). Increased risks were seen in current or recent users of any hormonal:
RR 1.30 (95% CI 1.20-1.42) and combined: RR 1.40 (95% CI 1.28-1.53), but not
progestin-only contraception: RR 0.91 (95% CI 0.78-1.07). Current or recent users of
any hormonal contraception had an increased risk of both adenocarcinoma (RR 1.29,
95% CI 1.05-1.60) and squamous cancer (RR 1.31, 95% CI 1.19-1.44). The risk pattern
among any hormonal and combined contraceptive users generally increased with lon-
ger duration of use and declined after stopping, possibly taking longer to disappear
among prolonged users. Combined products containing different progestins had simi-
lar risks. Approximately one extra cervical cancer occurred for every 14 700 women
using combined contraceptives for 1 year. Most women in our study were not vacci-
nated against human papillomavirus (HPV) infections. Our findings reinforce the
urgent need for global interventions such as systematic screening, treatment of cervi-
cal intraepithelial neoplasia and HPV vaccination programmes to prevent cervical can-
cer, especially among users of combined contraceptives.
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1 | INTRODUCTION
In 2018, approximately 570 000 new cases of cervical cancer (6.6% of
all new female cancers), and 311 365 related deaths occurred world-
wide.1 A necessary cause of cervical cancer is human papillomavirus
Abbreviations: BMI, body mass index; CI, confidence interval; HPV, human papillomavirus;
ICD, International Classification of Diseases; ICD-O-3, International Classification of Diseases
for Oncology 3rd edition; LNG-IUS, levonorgestrel-releasing intrauterine system; OR, odds
ratio; RR, relative risk; SIR, standardised incidence ratio.
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(HPV) infection with eight types of HPV found in 91% of cases of cer-
vical cancer worldwide.2 Currently available bivalent, quadrivalent and
nonavalent HPV vaccines provide the opportunity to prevent a large
proportion of cervical cancer cases. More than 80% of all cervical can-
cer cases occur in Africa, Asia, Latin America and the Caribbean. Most
countries within these regions do not have an HPV immunisation pro-
gramme.3,4 Vaccine shortages are ongoing and predicted to last at
least until 20255 resulting in a large number of women around the
world remaining at risk of HPV infection and cervical cancer.
Risk factors for cervical cancer include aspects of sexual behav-
iour, cigarette smoking, immunodeficiency and oral contraception.6 In
2019, an estimated 151 million women of reproductive age worldwide
used oral contraceptives, of which roughly two-thirds lived outside
Europe, North America, Australia and New Zealand.7 Thus, most oral
contraceptive users live in countries without comprehensive HPV vac-
cination or cervical screening programmes. Past evidence, summarised
by the International Collaboration of Epidemiological Studies of Cervi-
cal Cancer using pooled individual data from 24 studies worldwide,
found that current and recent use of combined oral contraceptives,
and possibly 5 or more years of progestin-only injectables, was posi-
tively associated with cervical cancer.8 The risk strengthened with
duration of use and waned after stopping, reaching that of never users
by about 10 years after cessation. Most of the evidence included in
the analysis, however, examined cervical cancer risk among the first
generation of combined oral contraceptive users exposed to prepara-
tions containing a high (50 μg or more) or medium (30-35 μg) dose of
oestrogen combined with an older progestin. Furthermore, the dura-
tion of use was relatively short. A more recent systematic review and
meta-analysis restricted to nine heterogeneous studies did not find an
altered cervical cancer risk among ever users of oral contraceptives,
odds ratio (OR): 1.21, 95% confidence interval (CI) 0.91-1.61.9 This
meta-analysis, however, did not examine current or recent, or former,
use separately. Another limitation was the inclusion of only studies
published between 2000 and 2012, in an attempt to assess the
effects of oral contraceptives similar to those currently marketed,
although several reports were of long-term follow-up of women using
older products.10,11 Presently, there is very limited direct evidence
informing users and their providers about whether contemporary hor-
monal contraceptives alter cervical cancer risk. We evaluated the risk
of cervical cancer among users of hormonal contraception in a large
cohort study of virtually all women of reproductive age and living in
Denmark; most of whom had not been vaccinated against HPV.
2 | MATERIALS AND METHODS
The previously described Danish Sex Hormone Register Study12,13
includes all women aged 15 to 79 years resident in Denmark and aims
to investigate hormone use and cancer, cardiovascular and psychiatric
diseases. For this analysis, we linked routinely collected data from the
National Register of Medicinal Product Statistics (for redeemed pre-
scriptions of all oral and non-oral forms of hormonal contraception
since January 1995); Statistics Denmark (for educational attainment);
the Danish Cancer Registry (for histologically verified cancers since
1943 and family history of premenopausal breast or ovarian cancer in
mothers or sisters); the National Health Register (for hospital dis-
charge diagnoses and surgeries since 1977) and the National Birth
Register (includes all births since 1973 and for parous women:
smoking status since 1991 and body mass index [BMI] since 2004).
These national datasets could be linked accurately because since
1968 each resident in Denmark has a unique personal identification
number in the Civil Registration System, and which is used by each
Register.
The eligible study population (n = 1 904 094) consisted of all
women aged 15 to 49 years living in Denmark from 1995 to 2014,
except those entering Denmark after 1995. Exclusions were women
with: treatment with ovarian stimulating drugs (Anatomical Therapeu-
tic Chemical Classification code MG03G), venous thrombosis, hyster-
ectomy or cancer (except non-melanoma skin cancer) before study
entry. After exclusions, the study population (n = 1 853 542) was
followed until the first diagnosis of cervical cancer (International Clas-
sification of Diseases [ICD] 10th revision14 code C53); death; age
50 or 31 December 2014 (end of follow-up). Women were censored
temporarily during pregnancy and for 6 months afterwards; and per-
manently at the date of venous thrombosis, ovarian stimulation drug
treatment, hysterectomy or diagnosis of different cancer (except non-
melanoma skin cancer).
2.1 | Statistical analysis
Analyses were conducted using SAS version 9.3 (SAS Institute, Inc,
Cary, NC). During the study, women were categorised according to
their use of hormonal contraception as current or recent (within 1 year
of stopping); former (more than 1 year since stopping) or ever (any hor-
monal contraceptive use during the study period) users. Never users
had no redeemed prescriptions for hormonal contraceptives recorded
at study entry or during the study period. If a woman was a never user
What's new?
Globally, millions of hormonal contraception users are
unvaccinated against human papillomavirus (HPV) infections,
which are known to cause cervical cancer. Little is known
about contemporary hormonal contraceptives and cervical
cancer risk. In this cohort of mostly unvaccinated women,
current or recent use of any hormonal and combined but not
progestin-only contraceptives increased cervical cancer risk.
The effect strengthened with increasing duration and took
longer to decline with prolonged use. The results reinforce
the urgency for global interventions to prevent cervical can-
cer including HPV vaccination programmes, systematic cervi-
cal screening and treatment of cervical intraepithelial
neoplasia, especially among users of combined
contraceptives.
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on entry to the study and then subsequently redeemed a prescription
for a hormonal contraceptive, her contraceptive status changed to cur-
rent or recent use on the date the prescription was redeemed. Women
could switch between current or recent and former user categories
depending on prescriptions redeemed. Once a woman became a user
of hormonal contraceptives, her contraceptive status could not return
to never use. There were fewer periods of observation among never
users because many of the women who were never users at study
entry subsequently redeemed a prescription for a hormonal contracep-
tive, at which point their contraceptive status changed.
Age-specific incidence of cervical cancer per 100 000 person-
years was calculated for the whole cohort. Using the age distribution
of the entire cohort as the standard, age-standardised incidence rates
of cervical cancer per 100 000 person-years were calculated for each
of the user groups.
Poisson regression was used to calculate the cervical cancer risk
among the different user groups, compared to never users. Adjusted
rate ratios (hereafter described as relative risk [RR]) with
corresponding 95% CIs allowed for time-varying covariates: hormonal
contraceptive use, calendar year, age (15-19, 20-24, 25-29, 30-34,
35-39, 40-44, 45-49 years), education (elementary school only, high
school only, further education excluding college/university, college/
university, university education with research qualifications,
unknown), tubal sterilisation (yes/no), endometriosis (yes/no), family
history of premenopausal breast or ovarian cancer (yes/no) and parity
(nulliparous, 1, 2, 3, 4, >4). Among parous women additional adjust-
ments were made for BMI (<18.5, 18.5-25, >25-30, >30 kg/m2) and
smoking status (non-smoker, current, unknown) determined during
pregnancy. We could not adjust for any aspects of sexual behaviour
(such as age at first intercourse, number of partners or use of barrier
contraceptives) since such information is not routinely collected by
the national registers used.
Duration (for any hormonal contraception, and users of combined
and progestin-only contraceptives separately) and time since last cur-
rent use were examined, with tests for trend performed by the inclu-
sion of the duration of time since last use variable as an ordinal
variable and values set to the median in each category.15 We exam-
ined tumour histology (coded using the International Classification of
Diseases for Oncology, 3rd edition, ICD-O-316 all ending with behav-
iour invasive digit 3) as squamous (M8052, 8070, 8071, 8072, 8076,
8083); adenocarcinoma (M8140, 8144, 8262, 8310, 8380, 8441,
8480, 8490, 9110) and mixed/indeterminate/other (all other morphol-
ogy codes provided with the C53 cancer registration).
We calculated risk estimates for different products in women
followed in the study until their first switch in hormonal contracep-
tion, recognising that there might be lingering effects from previous
use of hormonal contraceptives. Product-specific risk estimates were
also calculated using 30 to 35 μg ethinylestradiol plus levonorgestrel
preparations as the reference group. We performed exploratory ana-
lyses of risk estimates among the subset of women with complete
contraceptive histories that is, those aged 15 on or after 1 January
1995. In this subset, we also examined the number, and effect of,
receiving HPV vaccination (since these women were most likely to
have been vaccinated).
It is possible that some women begin using, or restart, hormonal
contraception because they experience symptoms such as heavy
bleeding, which are subsequently attributed to cervical cancer. It is also
possible that some women have a cervical smear around the time of
beginning or restarting hormonal contraception, providing an opportu-
nity for cervical cancer to be detected. In either situation, a short-term
increase in events could be observed among current users of hormonal
contraceptives, due to these factors rather than any biological effects
of the contraceptives. To investigate whether such protopathic bias
might have occurred, we undertook sensitivity analyses in which
periods of observation were ignored for 1 year before the date of cer-
vical cancer diagnosis. This resulted in the exclusion of 243 women
with less than 1 year of observation before cancer diagnosis.
We did not adjust for multiple comparisons. For the full cohort,
we calculated age-standardised absolute risks (incidenceexposed −
incidenceunexposed) and the number needed to harm
(1/incidenceexposed − incidenceunexposed).
3 | RESULTS
A total of 2339 incident cervical cancers occurred during
13 235 473 person-years among ever users of hormonal contracep-
tives and 1304 incident cervical cancers during 7 948 536 person-
years among never users. Among ever users of hormonal contracep-
tives, the median duration of use was 5.02 years (interquartile range
2.03, 8.89 years); the mean duration was 5.87 years
(SD = 4.51 years). Combined hormonal contraceptives accounted for
86% of all current or recent hormonal contraceptive use in the study
(Table 1S). The relatively popular levonorgestrel-releasing intrauter-
ine system (LNG-IUS) and desogestrel-containing progestin-only
pills tended to be used by parous rather than nulliparous women,
unlike other progestin-only products. Age-specific incidence of cer-
vical cancer increased until age 40, whereupon it fell (Table 1). The
age-adjusted incidence of cervical cancer in never users was 14.9
per 100 000 person-years and in ever users of any hormonal contra-
ceptives 17.8 per 100 000 person-years (Table 2). Compared to
never users, ever users of any hormonal contraceptives had an
increased risk of cervical cancer: RR 1.19 (95% CI 1.10-1.29); driven
by an increased risk among current or recent users: RR 1.30 (95% CI
1.20-1.42). Most of the risk associated with hormonal contraception
arose from the use of combined contraceptives.
Examined separately, current or recent users of combined contra-
ceptives had an increased risk of cervical cancer: RR 1.40 (95% CI
1.28-1.53), unlike current or recent users of progestin-only contracep-
tives: RR 0.91 (95% CI 0.78-1.07). Adjustment for BMI and smoking
status among parous women did not materially change the risk esti-
mates. For example, an increased cervical cancer risk was found
among parous ever users of any hormonal contraceptives: RR 1.10
(95% CI 1.01-1.21) and current or recent users: RR 1.19 (95% CI
IVERSEN ET AL. 771
1.08-1.31), but not among former users: RR 0.98 (95% CI 0.88-1.09)
(data not shown).
In analyses of both any hormonal and combined contraceptives,
there was a trend of increasing cervical cancer risk with duration of
current use. This relationship was not seen among users of progestin-
only products. When the entire dataset was examined, there was no
increased risk of cervical cancer among women who were more than
1 year since last current use (Table 2). However, when the data were
TABLE 1 Age-specific incidence per
100 000 of cervical cancer during the
period 1995 to 2015
Age group (y) Cervical cancer (n) Person-years Incidence per 100 000 person-years
15-19 <3a 3 155 580 n/a
20-24 136 2 878 558 4.7
25-29 455 2 784 600 16.3
30-34 744 2 987 372 24.9
35-39 878 3 213 356 27.3
40-44 825 3 265 173 25.3
45-50 603 2 901 373 20.8
aData not available for presentation due to less than three events, incidence estimate therefore not
available (n/a) and total person-years rounded to nearest five.















Never use 7 948 536 1304 14.9 1.00
Ever use (any hormonal) 13 235 473 2339 17.8 1.19 (1.10-1.29) 2.9 (1.8 to 4.1)
Former use (any hormonal) 4 412 259 872 16.0 1.02 (0.93-1.13) 1.1 (−0.4 to 2.5)
Current or recent use (any hormonal) 8 823 214 1467 19.8 1.30 (1.20-1.42) 4.9 (3.5 to 6.3)
Current or recent use (combined) 7 745 534 1269 21.7 1.40 (1.28-1.53) 6.8 (5.2 to 8.5)
Current or recent use (progestin-only) 1 077 679 198 14.5 0.91 (0.78-1.07) −0.4 (−2.7 to 1.9)
Duration of current use (any hormonal contraception)
≤1 y 1 262 551 173 23.9 1.37 (1.16-1.61)* 8.9 (5.1 to 12.8)
>1 to ≤5 y 4 055 910 462 17.2 1.14 (1.02-1.28) 2.3 (0.4 to 4.3)
>5 to ≤10 y 2 576 116 527 19.6 1.40 (1.24-1.57) 4.7 (2.6 to 6.8)
>10 y 928 636 305 23.0 1.55 (1.34-1.80) 8.1 (5.3 to 10.9)
Duration of current use (combined)
≤1 y 1 183 528 150 22.8 1.34 (1.12-1.59)** 7.9 (3.8 to 12.0)
>1 to ≤5 y 3 641 233 410 19.9 1.25 (1.11-1.41) 5.0 (2.4 to 7.6)
>5 to ≤10 y 2 202 125 441 20.8 1.46 (1.28-1.65) 5.9 (3.3 to 8.5)
>10 y 718 648 268 26.2 1.76 (1.51-2.05) 11.3 (8.0 to 14.6)
Duration of current use (progestin-only)
≤1 y 79 023 23 27.0 1.80 (1.19-2.71)*** 12.1 (1.0 to 23.2)
>1 to ≤5 y 414 678 52 10.7 0.71 (0.53-0.94) −4.2 (−7.4 to −1.0)
>5 to ≤10 y 373 991 86 22.0 1.16 (0.92-1.45) 7.1 (2.1 to 12.2)
>10 y 209 988 37 10.6 0.75 (0.54-1.06) −4.3 (−7.9 to −0.8)
Time since last current use of any hormonal contraception
>1 to ≤5 y 2 412 582 465 16.4 1.09 (0.97-1.22)¶ 1.5 (−0.3 to 3.3)
>5 to ≤10 y 1 360 077 292 16.0 1.03 (0.90-1.18) 1.1 (−1.4 to 3.5)
>10 y 637 600 115 11.5 0.79 (0.65-0.97) −3.4 (−6.9 to 0.0)
*p-Trend <.001, **p-Trend <.001, ***p-Trend = .303,
¶p-Trend <.001.
aAdjusted for: calendar year, education, age, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.
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stratified by duration of use and time since last use, there was evi-
dence that the risk among women with prolonged use may take lon-
ger to disappear (up to 10 years) than the risk among women with
shorter-term use (Table 3).
The overall risk estimates in the subset of women followed until
their first switch in hormonal contraceptive were of similar magnitude
to those seen in the full cohort (Table 4). We had insufficient data to
calculate risk estimates for some of the products used including vagi-
nal rings and contraceptive patches. Overall, there was little evidence
of major differences in risk between combined products containing
different progestins. Analyses where 30 to 35 μg ethinylestradiol plus
levonorgestrel products formed the referent group (Table 2S), and
when product-specific estimates were calculated among the full
cohort (Table 3S), also found few differences between products. In
both analyses, current or recent users of the LNG-IUS had a reduced
cervical cancer risk when compared to current or recent users of
30 to 35 μg ethinylestradiol plus levonorgestrel products.
Larger, but very imprecise, point estimates were observed in the
exploratory analysis among women with full contraceptive history (-
Table 4S). Former users of any hormonal contraception had an
increased risk of cervical cancer in this subset analysis: RR 4.35 (95%
CI 1.57-12.00). More than three-quarters of former users had stopped
within the previous 5 years (data not shown). In this subset, current or
recent use of progestin-only products was associated with increased
cervical cancer risk: RR 3.38 (95% CI 1.13-10.10). There was little evi-
dence of differences in the risk estimates of combined products con-
taining different progestins when compared against 30 to 35 μg
ethinylestradiol plus levonorgestrel products (Table 4S). More never
users in the full contraceptive history subset had received an HPV
vaccination than ever users (24.0% vs 9.7% periods of observation,
respectively) (Table 5S). The risk estimates in Table 4S changed very
little after also adjusting for HPV vaccination (data not shown).
Approximately three-quarters of the cervical cancers were squa-
mous (Table 5). Current or recent users of any hormonal contracep-
tion had an increased risk of both adenocarcinoma and squamous
tumour types.
Sensitivity analysis which excluded periods of observation 1 year
before diagnosis in the full cohort found that short duration (<1 year)
current use of combined or progestin-only hormonal contraceptives
was no longer positively associated with cervical cancer (Table 6S).
A similar sensitivity analysis of women followed up until their first
switch in hormonal contraception also found short-term current use
of any hormonal and combined contraceptives did not increase the
risk of cervical cancer (Table 7S).
Age-adjusted absolute risks were calculated for the main patterns
of contraceptive use in the entire cohort (Table 2). The age-adjusted
absolute risk of cervical cancer among current or recent use of com-
bined contraceptives was 6.8 per 100 000 (95% CI 5.2-8.5) person-
years; approximately one extra case of cervical cancer for every
14 706 women using combined contraceptives for 1 year.
4 | DISCUSSION
In this cohort study of mostly women unvaccinated for HPV, cur-
rent or recent use of any hormonal contraception and combined
contraception, but not progestin-only contraception, was associ-
ated with an increased risk of cervical cancer; an effect which
strengthened with increasing duration of use. The increased risk of
cervical cancer among women with prolonged use appeared to take
up to 10 years to disappear after stopping. Where there was suffi-
cient use of products to permit analysis, there was little evidence
of material differences in risk between different combined prepara-
tions. Current or recent use of any hormonal contraception was
positively associated with both squamous and adenocarcinoma
types of cervical cancer.
Our results indicate that currently used combined oral contracep-
tives are associated with a similar pattern of cervical cancer risk as
that of older preparations,8 at least among women not vaccinated
against HPV. We had insufficient data to assess robustly the risk asso-
ciated with combined contraceptive patches or vaginal rings. Most
studies published since the International Collaboration's publication
have investigated ever use of combined oral contraception.10,11,17-24
Several reported an increased risk of cervical cancer with prolonged
use10,11,17,18 and a waning risk with increasing time since last
use.11,17,21,24,25 None of the other studies provided product-specific
estimates. We found little evidence of major differences in risk
between combined products containing different progestins.
Based on 10 studies (out of 24 overall), the International Collabo-
ration found an increased risk of cervical cancer in women with 5 or
TABLE 3 Relative risk of cervical cancer in hormonal contraceptive users by time since last use and duration of use (all women)
Time since last current use
>1 to ≤5 y >5 to ≤10 y >10 y
Duration of use Person-years Events RR (95% CI)a Person-years Events RR (95% CI)* Person-years Events RR (95% CI)a
≤1 y 659 103 104 1.07 (0.87-1.31) 456 734 84 1.01 (0.81-1.28) 303 177 64 1.06 (0.81, 1.40)
>1 to ≤5 y 1 028 947 184 1.20 (1.01-1.42) 620 549 141 1.25 (1.03-1.52) 296 198 42 0.70 (0.50, 0.97)
>5 y 726 532 177 1.55 (1.27-1.89) 282 794 67 1.37 (1.03-1.83) 38 225 9 1.29 (0.65, 2.56)
Total 2 414 582 465 1 360 077 292 637 600 115
aAdjusted for: calendar year, education, age, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.
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TABLE 4 Relative risk of cervical cancer among users of different hormonal contraceptives in women followed up until first switch in
hormonal contraceptive
Person-years Cervical cancer (N) Adjusteda relative risk (95% confidence interval)
Never use 7 948 536 1304 1.00
Ever use (any hormonal) 7 127 336 1135 1.18 (1.08-1.28)
Former use (any hormonal) 2 540 968 491 1.04 (0.93-1.17)
Current or recent use (any hormonal) 4 586 368 644 1.29 (1.16-1.42)
Current or recent use (combined) 4 313 847 603 1.36 (1.22-1.51)
Current or recent use (progestin-only) 272 521 41 0.77 (0.57-1.06)
Current or recent use of combined hormonal contraception
Oral
Norethisterone 50 μg EE 36 407 18 2.69 (1.68-4.28)
Levonorgestrel 50 μg EE 47 171 15 1.59 (0.95-2.64)
Norethisterone 30-35 μg EE 115 988 23 1.73 (1.14-2.63)
Levonorgestrel 30-35 μg EE 518 647 123 1.48 (1.23-1.79)
Desogestrel 20-30 μg EE 988 333 112 1.21 (0.99-1.48)
Gestodene 20-35 μg EE 1 885 998 240 1.31 (1.13-1.52)
Drospirenone 20-35 μg EE 188 850 9 1.13 (0.58-2.19)
Norgestimate 35 μg EE 375 464 48 1.35 (1.01-1.80)
Cyproterone 30 μg EE 142 001 14 1.01 (0.59-1.71)
Estradiol valerate, dienogest 1010 <3 n/a
Non-oral
Patch 2250 <3 n/a
Vaginal ring 11 730 <3 n/a
Current or recent use of progestin-only contraception
Oral
Norethisterone 66 790 10 0.75 (0.40-1.40)
Levonorgestrel 6955 <3 n/a
Desogestrel 12 110 <3 n/a
Non-oral
MPA depot 7315 <3 n/a
Implant 10 555 <3 n/a
LNG-IUS 168 801 27 0.76 (0.52-1.11)
Duration of current use (any hormonal contraception)
≤1 y 1 059 532 135 1.30 (1.08-1.56)
>1 to ≤ 5 y 2 309 695 241 1.12 (0.97-1.29)
>5 to ≤10 y 960 337 185 1.43 (1.21-1.70)
>10 y 256 804 83 1.66 (1.31-2.11)
Duration of current use (combined)
≤1 y 1 000 606 120 1.29 (1.07-1.57)
>1 to ≤5 y 2 144 034 223 1.24 (1.06-1.44)
>5 to ≤10 y 919 330 177 1.48 (1.24-1.75)
>10 y 249 877 83 1.69 (1.33-2.15)
Duration of current use (progestin-only)
≤1 y 58 926 15 1.46 (0.87, 2.42)
>1 to ≤5 y 165 660 18 0.56 (0.35, 0.89)
>5 to ≤10 y 41 007 8 0.96 (0.48, 1.93)
>10 y 6930 <3 n/a
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more years of progestin-only injectable contraceptive use: RR 1.22
(95% CI 1.01-1.46).8 Risk estimates for progestin-only oral contracep-
tives could not be calculated. The Johannesburg Cancer Case Control
Study examined progestin-only injectable use and cervical cancer and
found that exclusive users of progestin-only injectables less than
10 years previously were more likely to be diagnosed with cervical
cancer than never users of hormonal contraceptives: OR 1.58 (95% CI
1.16-2.15).21 When time since last use and duration of use were
examined simultaneously, cervical cancer risk diminished with increas-
ing time since last use, without a relationship to duration of use.21
The results from both of these studies8,21 suggest an increased risk of
cervical cancer among progestin-only injectable users. The use of
MPA depot was rare in our cohort. Our main analyses did not reveal
an increased risk with current or recent use of any progestin-only con-
traceptives regardless of route of administration. Neither was there a
relationship with duration of current use. The exploratory subgroup
analysis of women with a complete contraceptive history did observe
increased (but very imprecise) risk estimates for progestin-only con-
traceptives, including for current or recent use of progestin-only prod-
ucts. This estimate may have been affected by a lingering effect of
previous use of combined contraceptives. Very few women in our
study used progestin-only products only and so we had limited statis-
tical power to detect effects for some of the progestin-only products.
The absence of cervical cancer risk among LNG-IUS users supports
findings from a nationwide cohort study of Finnish women aged
30-49 years using the LNG-IUS for menorrhagia, which found a
standardised incidence ratio (SIR) of 0.90 (95% CI 0.69-1.15) for all
cervical cancer and SIR 1.18 (95% CI 0.74-1.79) for cervical
adenocarcinoma.26
Strengths of our study include the ability to examine all types of
hormonal contraceptives used between 1995 and 2014 among a
nearly whole nation cohort of more than 1.8 million women of repro-
ductive age, observed for over 21 million person-years. Information
about both redeemed prescriptions for hormonal contraceptives and
incident cervical cancers are routinely collected prospectively by the
National Registers, thus avoiding information bias. When considering
specific products, our main risk estimates were calculated among
women followed until their first switch in hormonal contraceptive in
the study, to reduce the possibility that a risk estimate for a particular
product might reflect lingering effects from another previously used
hormonal contraceptive(s). There was little evidence of important dif-
ferences in risk estimates for combined contraceptives containing dif-
ferent progestins. Compatible results were found in the exploratory
analyses of women with a full contraceptive history, although the risk
estimates were much less precise because they were based on fewer
cervical cancers (n = 285) and less periods of observation (25%) than
TABLE 4 (Continued)
Person-years Cervical cancer (N) Adjusteda relative risk (95% confidence interval)
Time since last current use of any hormonal contraception
>1 to ≤5 y 1 267 925 225 1.08 (0.93-1.25)
>5 to ≤10 y 808 397 180 1.10 (0.93-1.30)
>10 y 464 646 86 0.85 (0.67-1.08)
Note: <3: data not available for presentation due to less than three events, estimate therefore not available (n/a) and total person-years rounded to
nearest five.
Abbreviations: EE, ethinylestradiol; LNG-IUS, levonorgestrel-releasing intrauterine system.
aAdjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.
TABLE 5 Relative risk of different histological types of cervical cancer associated with hormonal contraception (all women)
Histology Person-years Cervical cancer (N) Adjusteda relative risk (95% confidence interval)
Squamous 2720
Never use 7 948 536 991 1.00
Current or recent use 8 823 214 1090 1.31 (1.19-1.44)
Former use 4 412 259 639 1.03 (0.92-1.15)
Adenocarcinoma 626
Never use 7 948 536 209 1.00
Current or recent use 8 823 214 257 1.29 (1.05-1.60)
Former use 4 412 259 160 0.98 (0.77-1.24)
Mixed/indeterminate/others 297
Never use 7 948 536 104 1.00
Current or recent use 8 823 214 120 1.29 (0.95-1.74)
Former use 4 412 259 73 1.08 (0.76-1.52)
aAdjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.
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in the main analysis. Although we could adjust for several possible
confounders, we lacked information about cervical screening, age at
first intercourse or number of sexual partners so residual confounding
could have occurred. That said, the International Collaboration found
similar patterns of risk among women likely to have been screened as
among those not screened, and in the subgroup of women who tested
positive for high-risk HPV compared to all women studied.8 Informa-
tion about lifetime number of sexual partners was available in all of
the case-control but none of the cohort studies included in the pooled
analysis. However, there was little difference in results using all stud-
ies, compared to the findings of only case-control studies that is, the
patterns of increased cervical cancer risk associated with oral contra-
ceptive use persisted after adjustment for sexual behaviour. Adjust-
ment for HPV serology did not materially change the cervical cancer
and oral contraceptive use findings from the European Prospective
Investigation into Cancer and Nutrition.23 We could adjust for BMI
and smoking status only among parous women, and then for only part
of the follow-up period. Although these adjustments did not substan-
tially alter the risks estimates, again it is possible that our results are
subject to residual confounding. Previous studies have suggested that
users of combined oral contraceptives are more likely to smoke than
non-users of these contraceptives.10,24 If this remains the case,
incomplete adjustment for smoking may have overestimated the risk
of cervical cancer among combined contraceptive users.
Hormonal contraceptives may exert molecular effects through
which persistent HPV infection leads to cervical cancer. For example,
oestrogen and progestin might promote HPV 16 E6 and E7 oncogene
expression, stimulating p53 tumour suppressor gene degradation and
viral DNA integration and transformation of cells to induce cancer devel-
opment.8,23,27 Other postulated mechanisms include, changed cervical
susceptibility to HPV infection, or altered HPV infection natural history
leading to reduced clearance.8,23,27 It is not clear whether and how these
mechanisms might be different for progestin-only contraceptives.
The Danish childhood immunisation programme for 12-year-old
girls has included HPV vaccination since 2009.28 Thus, our findings
reflect the risks associated with hormonal contraception in a predomi-
nantly unvaccinated cohort. The absence of material change after
adjusting for HPV vaccination in the full contraceptive subset was
likely due to the small proportion of person-time attributable to HPV
vaccinated women. Given recent evidence from Sweden that girls and
women aged 10 to 30 who received the quadrivalent HPV vaccination
had a substantially reduced risk of invasive cervical cancer,29 we await
the opportunity to determine whether HPV vaccination within our
cohort reduces cervical cancer incidence. Such an effect would
increase the number needed to harm from combined oral
contraceptive use.
In our cohort of women mostly unvaccinated for HPV, we esti-
mate that one extra case of cervical cancer occurred in our cohort for
every 14 706 women who used contemporary combined contracep-
tion for 1 year. The absolute risk will be higher in countries where cer-
vical cancer is more common than in Denmark; countries where
comprehensive screening and HPV vaccination programmes are often
absent and where perhaps two-thirds of all hormonal contraceptive
users live. Women should be informed of the association between
contemporary combined contraception and cervical cancer, an effect
which is enhanced by prolonged use but which disappears some years
after stopping. Such information should be balanced against high
levels of protection against pregnancy and its associated mortality and
morbidity, and other important non-contraceptive benefits including
large sustained protection against ovarian30 and endometrial31 cancer.
Our results indicate that currently available combined contracep-
tives continue to be positively associated with the risk of cervical can-
cer, at least among women not vaccinated against HPV. Women
wishing to use this method of contraception need to be informed of
this risk and encouraged to participate in a cervical screening pro-
gramme, if available. They should also be alert to any symptoms indic-
ative of cervical cancer, and report these promptly to their health care
provider. Our findings also reinforce the urgent public health need for
global interventions to prevent cervical cancer.
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